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LDL-C control compared to those without CIC, suggesting that integrated systems 
may be beneficial to those with CIC.
PDB9
EffEct of thyroiD hormonE lEvEls on alPha human hErPEs virusEs 
latEncy anD rEactivation
Parmar J.R., Ajavon A., Balish M., Hsia V., Freeman R.
University of Maryland Eastern Shore, Princess Anne, MD, USA
Objectives: The first aim of this study is to collect individual-level patient data 
for a retrospective cohort study examining the demographics of patients diagnosed 
with Alpha Human Herpes Viruses (α -HHV) infection, and patients with low Thyroid 
levels (Thyroid disorder) over a 6-year period. The second aim is to test statistically 
that low Thyroid levels are related to higher prevalence of α -HHV. MethOds: The 
data will be obtained from Peninsula Regional Medical Center located in Salisbury, 
Maryland. The adjusted medical claims will be identified using ICD-9-CM codes for 
the study period 2006-2012 of Thyroid disorders (240XX-246XX), HSV-1 (054XX) and 
VZV (053XX). The unique patients included in the sample will be identified with at 
least one medical claim for Thyroid disorder, and α -HHV diagnosis during the study 
period. Statistical analyses will be done using 2x2 contingency table developed 
by using patients with Thyroid disorder only, patients with α -HHV diagnosis only, 
patients that have both Thyroid disorder plus α -HHV diagnoses, and all patients 
without Thyroid or α -HHV diagnosis. The abstraction of the data will be done using 
Microsoft® Access and the statistical analysis will be done using SAS®9.3. Results: 
The preliminary analysis of the data revealed there were 4,551 patients with Thyroid 
disorder only, 217 patients with α -HHV diagnosis only, 85 patients that have both 
Thyroid disorder plus α -HHV diagnoses, and 1,46,963 patients without Thyroid or 
α -HHV diagnosis. The Odds ratio = 12.65 and p-value < 0.0001 (95% confidence 
Interval). cOnclusiOns: The preliminary analysis reveals that odds of α -HHV reac-
tivations are approximately twelve times higher for the individuals with Thyroid 
disorders. And, Thyroid disorders are significantly associated with higher prevalence 
of α -HHV.
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Objectives: Public and private US Payers use CQM to assess the quality of diabetes 
care and to incentivize improvement in care and associated outcomes. Examples 
of payers using CQMs include the Medicare Shared Savings Program (MSSP) and 
HealthPartners (HP). This post hoc analysis assessed CQM attainment with CANA 
and SITA in overweight/obese patients with T2DM. MethOds: This analysis used 
pooled data from 2 previously published comparative randomized controlled clini-
cal trials that evaluated CANA and SITA treatment in patients with inadequate 
glycemic control on current therapy. CQM attainment was defined as achievement 
of combined glycated hemoglobin (HbA1c), blood pressure, and low density lipo-
protein cholesterol (LDL-C) thresholds. CQM attainment was assessed at baseline 
and 52 weeks, using last observation carried forward. Differences between CANA 
and SITA treatment groups were evaluated using 95% confidence intervals (CI) and 
odds ratios (OR) based on logistic regression. Results: Baseline characteristics of 
645 CANA and 649 SITA treated patients with body mass index > 25 kg/m42 and data 
for CQM assessment were similar. Baseline CQM attainment was similar between 
groups. At 52 weeks, CANA vs SITA demonstrated a greater likelihood of attaining 
CQMs. For the HP CQM HbA1c< 7%;BP< 130/80mmHg;LDL-C< 100mg/dL, CANA dem-
onstrated 4.9% (95% CI 1.2;8.5 and OR 1.94, 95% CI 1.30;2.91 ) better attainment. For 
the MSSP CQM HbA1c< 8%;BP< 140/90mmHg;LDL-C< 100mg/dL CANA demonstrated 
6.6% (95% CI 1.4;11.9 and OR 1.58, 95% CI 1.19;2.08) better attainment. Hypoglycemia 
rates for each group were similar. CANA was associated with higher rates of genital 
mycotic infections and adverse events related to osmotic diuresis, but with few 
study discontinuations. cOnclusiOns: Compared to SITA 100 mg, CANA 300 mg 
treatment was associated with better CQM attainment in obese/overweight patients 
with T2DM. This information may inform payers on the comparative effectiveness of 
antihyperglycemic agents on attainment of diabetes CQMs which include glycemic, 
blood pressure, and lipid endpoints.
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Objectives: The objective was to examine the evidence on the efficacy of current 
treatments in patients with Cushing’s disease (CD) to support health care decision-
making. MethOds: A systematic literature search using predefined strategy was 
performed in the Cochrane library, EMBASE, PUBMED and MEDLINE to identify 
observational studies in North America and Europe from 2003 to 2013. A total of 
32 studies were included and analyzed, out of 791 studies found. Results: For 
primary CD (n= 23/32), transsphenoidal surgery (TSS) remains the procedure of 
choice (n= 20/23, 87% of studies). For recurrent/persistent disease (n= 11/32), treat-
ment received was; TSS in 36.3%, radiotherapy in 27.35%, bilateral adrenalectomy 
(BLA) in 18.2% and medical therapy in 18.2%. Remission rates post primary TSS 
were 65%-91% with recurrence of 5%-24%. Variability in remission rate could be 
attributed to the lack of uniformity in the definition for remission, different length 
of follow-up, patient population (macro- vs. micro-adenomas), surgeon experience 
and the type of TSS technique used (endoscopic vs. microscopic). Remission rate was 
lower for recurrent/persistent CD (37.5%-71%).Major complications were; diabetes 
PDB6
thE PotEntial carDiovascular risk of rosiglitazonE comParing to 
othEr anti-DiaBEtEs agEnts: a rEtrosPEctivE DEscriPtivE stuDy
Deng Y, Guo J.J., Lin A.C.
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA
Objectives: The discussion around the cardiovascular risk caused by rosiglitazone 
continues, as the results from recent pharmacoepidemiologic studies were believed 
inconclusive. The objective of this study is to do a descriptive study on the adverse 
events, especially cardiovascular events caused by rosiglitazone and other com-
monly used anti-diabetes agents. MethOds: FDA adverse event reporting system 
(FAERS) database was used for data analysis; reports were drawn from 1997 to 2011. 
Study drugs include rosiglitazone, pioglitazone, metformin, glipizide and glyburide. 
Adverse events during time were calculated to see the trend. Frequency of different 
adverse events described and stratified by age and gender. Different outcomes like 
the cardiovascular events, death and hospitalization associated with each study 
drug were calculated each year. Results: The adverse events of all drugs did not 
vary much during years, except that rosiglitazone has a sharply increase from 
2008 and decreased in 2011, in accordance with the 2007 meta-analysis published. 
Adverse events of different drugs differ in gender: there are 10% more adverse 
events of glyburide and 14% more of rosiglitazone in male than female; while met-
formin cause 8% more in female than male. Rosiglitazone has significantly more 
deaths (5568) and hospitalizations (28387) comparing to other four drugs (average 
2225 death and 11521 hospitalization), and it also has more cardiovascular events 
(36.37%) than other four drugs (average 11.52%). cOnclusiOns: Rosiglitazone 
seems to have more and severe adverse events, especially cardiovascular events 
comparing to other four antidiabetic drugs.
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Objectives: Intramuscular (IM) testosterone injections have been available since 
1953 but significant immediate adverse reactions have not been well documented. 
The objective was to estimate the rate of anaphylaxis associated with IM testoster-
one injections. MethOds: This retrospective analysis utilized a large commercial 
claims database. Study sample consisted of males who received office-based IM 
testosterone injection(s) between 2007 and 2011. Anaphylaxis cases were selected 
from medical claims based on the ICD-9-CM 995.0 (other anaphylactic reaction), 
occurring on the same day of the testosterone injection. The relationship between 
testosterone injections and anaphylaxis were classified as “likely, probably, pos-
sible, unlikely” based on the clinical review of patient’s medical history, treatment 
for anaphylaxis and existence of confounding diagnoses. The outcomes were the 
number of patients with anaphylaxis per 10,000 patients and the number of anaphy-
laxis cases per 10,000 person-years. Results: Between 2007 and 2011, 989,778 IM 
testosterone injections were identified for a total of 120,402 males (mean age: 49.1 
years). A total of 232 patients had at least one anaphylaxis claim within 365 days of 
receiving an IM testosterone injection. Among 40 same-day anaphylaxis cases (39 
patients), there were 12 cases (12 patients) with anaphylaxis classified as “likely” 
or “probable”, which represent a rate of 1.0 patient per 10,000 patients, or 1.5 cases 
per 10,000 person-years. There were 17 cases (16 patients) with anaphylaxis classi-
fied as “likely”, “probable”, or “possible”. In comparison, there were only 19 cases of 
anaphylaxis identified from the FDA Adverse Event Reporting System (FAERS) from 
1/1969 to 1/2013 (44 years). cOnclusiOns: Our study showed that, although rare, 
anaphylaxis-related events have been documented to occur following IM testos-
terone injections. Given the limitations of spontaneous reporting of adverse events 
for marketed products, claims databases can be utilized to complement FAERS in 
identifying safety signals for drugs, especially older drugs.
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Objectives: To assess clinical outcomes among individuals having chronic illness 
with complexity (CIC) defined as co-occurring type 2 diabetes mellitus (T2DM) 
and Parkinson’s disease (PD). MethOds: This study used a retrospective cohort 
design using Humana Medicare Advantage Part D claims database (2007-2011) and 
included elderly (age ≥ 65 years) Medicare beneficiaries with T2DM (identified by 
ICD-9-CM code of 250.x0 or 250.x2). PD was identified using ICD-9-CM code of 332.
xx. Individuals with T2DM and PD (CIC) were matched to those with T2DM and no 
PD (no CIC) on sex, age, and diabetes complications severity index based on 8 to 1 
GREEDY matching algorithm using propensity score. After propensity score match-
ing there were 2,703 individuals with T2DM and PD and 8,109 with T2DM and no PD. 
Glycemic control outcomes [(i) < 8%, (ii) ≥ 8%, (iii) no HbA1c values] and lipid control 
outcomes [based on Low Density Lipoprotein Cholesterol (LDL-C) categorized into 
(i) < 100 mg/dl, (ii) ≥ 100mg/dl, (iii) no LDL-C values] were measured during the year 
subsequent to the identification of T2DM and PD. Multinomial conditional logistic 
regressions were conducted to examine the association between PD and clinical 
outcomes. Results: Among those with laboratory values, 86.1% individuals with 
PD and 83.8% individuals without PD had < 8% HbA1c value; the corresponding fig-
ures for LDL-C value of < 100mg/dl were 75.5% and 69.8% respectively. Multinomial 
conditional logistic regressions revealed that individuals with PD were more likely 
than those without PD to have good glycemic control of < 8% HbA1c (reference group: 
≥ 8% HbA1c) (AOR: 1.34, 95%CI: 1.10-1.63) and good LDL-C control of < 100mg/dl 
(reference group: ≥ 100mg/dl LDL-C) (AOR: 1.29, 95%CI: 1.03-1.63). cOnclusiOns: 
Individuals with CIC were more likely to have clinically recommended glycemic and 
